Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy

Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.

Prostate is the last solid organ malignancy that is diagnosed by randomly sampling the gland, says Rastinehad.

A transperineal MR/TRUS fusion biopsy system has been developed that tracks the probe and needles with EM tracking. This technology has potential for application in transperineal focal therapy.

The system is FDA cleared for treatment, so oncologists can diagnosis and treat specific areas in the prostate. This may reduce the need for radiation and/or surgery.